Baseline demographic data, clinical characteristics, and comorbidities
| Experimental group (SINR) n=108 | Placebo group n=107 | P value | |
| Mean age (±SD), years | 62.5 (6.6) | 62.9 (6.7) | 0.662 |
| Mean body mass index (±SD), kg/m2 | 31.40 (4.48) | 31.33 (4.44) | 0.903 |
| Male gender, n (%) | 31 (28.7) | 39 (36.5) | 0.226 |
| Duration of type 2 diabetes mellitus | |||
| <2 years 2–5 years 5–10 years 10–15 years >15 years | 3 (2.8%) 18 (16.7%) 28 (25.9%) 31 (28.7%) 28 (25.9%) | 4 (3.7%) 19 (17.8%) 26 (24.3%) 36 (31.2%) 22 (20.6%) | 0.856 |
| Treated by insulin injections, n (%) | 40 (36.7) | 40 (37.4) | 0.917 |
| Duration of DPN | |||
| <1 year 2–3 years 4–5 years >5 years | 14 (13.0%) 20 (18.5%) 46 (42.6%) 28 (25.9%) | 13 (12.2%) 24 (22.4%) 48 (44.9%) 22 (20.6%) | 0.763 |
| Diabetic retinopathy, n (%) | 18 (9.3) | 21 (19.6) | 0.030 |
| Diabetic nephropathy, n (%) | 18 (16.7) | 19 (17.8) | 0.832 |
| Diabetic macroangiopathy, n (%) | 5 (4.6) | 10 (9.4) | 0.175 |
| Arterial hypertension, n (%) | 96 (88.9) | 92 (86.0) | 0.520 |
| Dyslipidemia, n (%) | 43 (39.8) | 46 (43.0) | 0.636 |
| Ischemic heart disease, n (%) | 31 (28.7) | 35 (32.7) | 0.524 |
DPN, diabetic polyneuropathy; SINR, succinic acid+inosine+nicotinamide+riboflavin.